Affordable, regulated versions of Ozempic, the well-known diabetes and weight-loss shot from Novo Nordisk, are about to hit markets around the world, which could shake up the obesity drug scene.
The change comes as patents on semaglutide, the active ingredient in Ozempic and related drugs like Wegovy, begin expiring in Canada, India, China and Brazil, Bloomberg reports.
